What Is In Vitro?

In vitro, from the Latin for "in glass," refers to experimental or analytical work conducted in a controlled laboratory environment outside of a living organism, typically using isolated cells, tissues, biological molecules, or biochemical reagents maintained in culture vessels or other defined systems. The term distinguishes these experiments from in vivo studies, which are carried out within living animals or humans, and from in silico approaches, which use computational models. In vitro methods are foundational to biomedical research, pharmaceutical development, toxicology, and the testing of medical devices, providing a controlled and reproducible environment in which variables can be manipulated systematically and observations made under defined physical and chemical conditions. The field draws on cell biology, biochemistry, analytical chemistry, and increasingly on microfluidics and bioengineering to produce models of biological processes at scales ranging from single molecules to multi-tissue systems.

Cell and Tissue Culture Methods

The most common in vitro platform is the cell culture, in which cells derived from organisms are grown and maintained outside the body under defined temperature, gas composition, and nutrient conditions. Adherent cultures grow as monolayers attached to flat surfaces such as treated polystyrene flasks or glass slides, while suspension cultures maintain non-adherent cells in liquid medium. Primary cultures are derived directly from excised tissue and retain many of the characteristics of the source organism, but typically have a limited proliferative lifespan. Established cell lines, such as the HeLa cervical cancer line or the HEK-293 kidney line, can be propagated indefinitely and provide reproducible experimental material, but may differ substantially from the cells and tissue they nominally represent. Three-dimensional culture systems, including multicellular spheroids, organoids derived from stem cells, and scaffold-supported tissue constructs, better replicate the spatial architecture, cell-cell contacts, and gradients of oxygen and nutrients found in native tissue, addressing a key limitation of two-dimensional monolayer models.

In Vitro Bioassays and Screening

Bioassays measure the effect of a test substance or condition on a biological endpoint using cells or biochemical systems as the detector. Cell viability assays quantify the fraction of live cells after exposure to a compound, using colorimetric indicators such as MTT or fluorescent markers that report metabolic activity or membrane integrity. Cytotoxicity, proliferation, migration, and invasion assays extend this to characterize how compounds affect specific cellular behaviors relevant to cancer, wound healing, or infection. High-throughput screening (HTS) platforms automate these assays across libraries of thousands to millions of compounds in microplate formats, enabling early identification of drug candidates. As described in a PMC review of cell-based screening methods in drug discovery, cell-based assays offer more physiologically relevant information than purely biochemical screens because they report compound activity within the context of an intact cellular environment, including membrane permeability, intracellular metabolism, and signaling pathway interactions. The NCI60 panel of 60 human tumor cell lines has served since 1990 as a standardized in vitro oncology screening resource, providing comparative sensitivity profiles across cancer cell types for new compounds.

Limitations and Advances Toward Physiological Models

A persistent challenge of in vitro research is that results obtained in simplified culture systems do not always predict outcomes in whole organisms, and compounds that appear effective against cancer cells in 2D monolayers have repeatedly shown reduced efficacy in clinical trials. NIH PMC research on cell culture-based test systems for anticancer drug screening documents how 3D spheroid models show greater drug resistance relative to 2D cultures, better reflecting the hypoxic gradients and stromal interactions present in tumors in vivo. Organ-on-a-chip microfluidic devices represent a further advance, recreating tissue-specific fluid flow, shear stress, and multi-cell-type architecture within micrometer-scale chambers to produce functional units that mimic lung, liver, gut, and heart tissue behavior. As discussed in NIH PMC work on recent advances in cell culture platforms for drug screening and cell therapies, microfluidic in vitro models improve translatability to clinical outcomes while reducing reliance on animal studies, though regulatory acceptance of these newer platforms as replacements for established test methods continues to develop.

Applications

In vitro methods have applications across a wide range of biomedical and life science fields, including:

• Pharmaceutical drug discovery, for early-stage efficacy and toxicity screening before animal and clinical studies
• Oncology research, for testing targeted therapies against tumor cell lines and patient-derived organoids
• Regulatory toxicology, for assessing chemical and material safety under guidelines such as ISO 10993 for medical devices
• Virology and vaccine development, for propagating viruses, measuring neutralizing antibody titers, and assessing antiviral compound activity
• Biomedical device testing, for evaluating the cytotoxicity and biocompatibility of materials that will contact living tissue